Re: The influence of statin medications on prostate-specific antigen levels.
作者信息
Cicero Arrigo F G, Derosa Giuseppe, Gaddi Antonio V
出版信息
J Natl Cancer Inst. 2009 Apr 15;101(8):610; author reply 610-1. doi: 10.1093/jnci/djp042. Epub 2009 Apr 7.
PMID:19351921
Abstract
摘要
相似文献
1
Re: The influence of statin medications on prostate-specific antigen levels.
J Natl Cancer Inst. 2009 Apr 15;101(8):610; author reply 610-1. doi: 10.1093/jnci/djp042. Epub 2009 Apr 7.
2
The influence of statin medications on prostate-specific antigen levels.
J Natl Cancer Inst. 2008 Nov 5;100(21):1511-8. doi: 10.1093/jnci/djn362. Epub 2008 Oct 28.
3
Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
J Natl Cancer Inst. 2009 Apr 15;101(8):611-2. doi: 10.1093/jnci/djp043. Epub 2009 Apr 7.
4
Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
J Natl Cancer Inst. 2008 Nov 5;100(21):1487-8. doi: 10.1093/jnci/djn368. Epub 2008 Oct 28.
5
The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report.
J Urol. 2005 Jun;173(6):1923-5. doi: 10.1097/01.ju.0000158044.94188.88.
6
Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
J Natl Cancer Inst. 2009 Mar 18;101(6):362-3. doi: 10.1093/jnci/djp028. Epub 2009 Mar 10.
7
Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.
J Clin Oncol. 2008 Feb 20;26(6):823-4. doi: 10.1200/JCO.2007.15.1902.
8
Study supports PSA velocity risk count.
J Natl Cancer Inst. 2012 Jul 18;104(14):1042-3. doi: 10.1093/jnci/djs324. Epub 2012 Jul 9.
9
[Prostate-specific antigen in early detection of prostate cancer].
Dtsch Med Wochenschr. 1997 Apr 18;122(16):529.
10
Statins and prostate cancer prevention: where we are now, and future directions.
Nat Clin Pract Urol. 2008 Jul;5(7):376-87. doi: 10.1038/ncpuro1146. Epub 2008 Jun 10.
Zotero 插件